R
Roy Taylor
Researcher at Newcastle University
Publications - 267
Citations - 16223
Roy Taylor is an academic researcher from Newcastle University. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 57, co-authored 258 publications receiving 13314 citations. Previous affiliations of Roy Taylor include Freeman Hospital & Southampton General Hospital.
Papers
More filters
Journal ArticleDOI
Periodontitis and diabetes: a two-way relationship
Philip M. Preshaw,A. L. Alba,David Herrera,Søren Jepsen,A K Konstantinidis,Konstantinos Makrilakis,Roy Taylor +6 more
TL;DR: Emerging evidence to support the existence of a two-way relationship between diabetes and periodontitis, with diabetes increasing the risk for periodontococcal inflammation, andperiodontal inflammation negatively affecting glycaemic control is supported.
Journal ArticleDOI
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean,Wilma S Leslie,Alison C. Barnes,Naomi Brosnahan,George Thom,Louise McCombie,Carl Peters,Sviatlana Zhyzhneuskaya,Ahmad Al-Mrabeh,Kieren G. Hollingsworth,Angela M. Rodrigues,Lucia Rehackova,Ashley J. Adamson,Falko F. Sniehotta,John C. Mathers,H. M. Ross,Yvonne McIlvenna,Renae J. Stefanetti,Michael I. Trenell,Paul Welsh,Sharon Kean,Ian Ford,Alex McConnachie,Naveed Sattar,Roy Taylor +24 more
TL;DR: The findings show that, at 12 months, almost half of participants achieved remission to a non-diabetic state and off antidiabetic medications, from baseline to 12 months.
Journal ArticleDOI
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol
E. L. Lim,Kieren G. Hollingsworth,Benjamin S. Aribisala,M J. Chen,John C. Mathers,Roy Taylor +5 more
TL;DR: Normalisation of both beta cell function and hepatic insulin sensitivity in type 2 diabetes was achieved by dietary energy restriction alone, and was associated with decreased pancreatic and liver triacylglycerol stores.
Journal ArticleDOI
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Jill J. F. Belch,Angus MacCuish,Iain C. Campbell,Stuart M. Cobbe,Roy Taylor,Robin J Prescott,Robert J. Lee,Jean Bancroft,Shirley MacEwan,James Shepherd,Peter W. Macfarlane,Andrew D. Morris,Roland T. Jung,C. Kelly,Alan Connacher,Norman R. Peden,Andrew Jamieson,David R. Matthews,Graeme Leese,John A. McKnight,Iain O’Brien,C. G. Semple,John R. Petrie,Derek Gordon,Stuart D. Pringle,Ron MacWalter +25 more
TL;DR: This trial does not provide evidence to support the use of aspirin or antioxidants in primary prevention of cardiovascular events and mortality in the population with diabetes studied.
Journal ArticleDOI
Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.
TL;DR: TNF-α neutralization over a period of 4 weeks had no effect on insulin sensitivity in obese NIDDM subjects and C-peptide remained unaffected by the type of treatment throughout the study.